AGOURA HILLS, Calif. , June 01, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun , Vuong Trieu . Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated
Treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease
AGOURA HILLS, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published April 24 th , is a special report in the biomedical journal Annals of Pulmonary and Critical Care
AGOURA HILLS, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19
In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements OT-101 which continues to demonstrate potent activity against SARS-CoV-2 and expands the company’s
OT-101 - a TGF- β 2 antisense - has demonstrated potent antiviral activity against COVID-19 OT-101 is part of the Company’s proprietary platform for rapid antiviral response to COVID-19 and future viral epidemics AGOURA HILLS, Calif. , April 06, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
AGOURA HILLS, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD PhD, Sanjive Qazi PhD, and Vuong Trieu , PhD in the oncology journal Cancer Reports and Reviews.
OT-101 and two additional candidates demonstrated viral inhibition activity against coronavirus AGOURA HILLS, Calif. , March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an
AGOURA HILLS, Calif. and DEERFIELD, Ill. , March 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI) enabled EdgePoint projects by expanding their partnership with Meridian IT, a leading technology
OT-101- a TGF- β 2 inhibitor - has demonstrated potent antiviral activity against coronavirus OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral response AGOURA HILLS, Calif. , March 18, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
